ClinicalTrials.gov
ClinicalTrials.gov Menu

Vaginal Estriol Before and Vaginal Surgery for Prolapse (VSaE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02906111
Recruitment Status : Unknown
Verified September 2016 by Salvatore Caruso, Policlinico Universitario, Catania.
Recruitment status was:  Not yet recruiting
First Posted : September 19, 2016
Last Update Posted : September 19, 2016
Sponsor:
Information provided by (Responsible Party):
Salvatore Caruso, Policlinico Universitario, Catania

Brief Summary:
The purpose of this study is to determine whether the vaginal estriol before vaginal surgery for pelvic statics disorders is more efficacy of no estriol treatment on vaginal health and quality of life.

Condition or disease Intervention/treatment Phase
Genital Prolapse Drug: estriol Procedure: vaginal surgery Phase 4

Detailed Description:
The aim of this randomized study was to evaluate the efficacy of low concentration of vaginal estriol gel (0.005%, 50 micrograms/1 g vaginal gel) in women with pelvic statics disorders before vaginal surgical treatment (group A), assessing the vaginal dryness, dysuria, vaginal maturation index (VMI), pH and the Vaginal Health Index (VHI). Secondary, to investigate the changes of sexual function and QoL. Women without pre surgical estriol treatment constituted the control group (group B).

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 88 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effects on Vaginal Health and Quality of Life in Postmenopausal Women Using Ultra Low Topic Estriol Before Vaginal Surgery for Pelvic Statics Disorders
Study Start Date : November 2016
Estimated Primary Completion Date : June 2017
Estimated Study Completion Date : June 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Estriol

Arm Intervention/treatment
Active Comparator: Study Group on estriol vaginal gel
Drug: 1 g/daily of vaginal gel containing 50 μg of estriol (0.005%) for 3 weeks and then twice weekly for 9 weeks, for a complete cycle of treatment of 12 weeks
Drug: estriol

Study Group, treated with estriol

Control Group, no drug treatment

Both groups will undergo vaginal surgery for prolapse


Procedure: vaginal surgery
Control Group
Other Name: vaginal surgery for prolapse

Active Comparator: Control group, no estriol treatment
Procedure: vaginal surgery
Procedure: vaginal surgery
Control Group
Other Name: vaginal surgery for prolapse




Primary Outcome Measures :
  1. Vaginal Health Indexes [ Time Frame: vaginal gel containing 50 µg of estriol, daily, for a complete cycle of treatment of 12 weeks ]

Secondary Outcome Measures :
  1. QoL and sexual function were investigated by the Short Form 36 (SF-36) [ Time Frame: vaginal gel containing 50 µg of estriol, daily, for a complete cycle of treatment of 12 weeks ]
  2. Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire short form (PISQ-12), respectively [ Time Frame: vaginal gel containing 50 µg of estriol, daily, for a complete cycle of treatment of 12 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   56 Years to 63 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • genital dryness,
  • irritation/burning/itching of vulvas or vagina
  • decreased lubrication with sexual activity
  • discomfort or pain with sexual activity
  • decreased arousal, orgasm, desire
  • dysuria.

Exclusion Criteria:

  • previous surgeries for pelvic organ prolapse
  • urinary incontinence
  • usage of medication
  • chronic medical illness
  • body mass index (BMI) ≥ 35 kg/m2
  • endometrial thickness equal to or greater than 4 mm
  • abnormal uterine bleeding
  • hormone-dependent malignancies
  • history of thromboembolic disease
  • liver disease
  • usage of HT for less than 3 months
  • usage of phytoestrogens within 1 month before the start of the study
  • partner affected by sexual disorder
  • conflicting with the partner

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02906111


Contacts
Contact: Salvatore Caruso, Prof +390953781101 scaruso@unict.it

Sponsors and Collaborators
Salvatore Caruso
Investigators
Study Chair: Antonio Cianci, Prof Policlinico Catania

Publications of Results:
Responsible Party: Salvatore Caruso, Professor of Gynecology, Clinic of Gynecology, Policlinico Universitario, Catania
ClinicalTrials.gov Identifier: NCT02906111     History of Changes
Other Study ID Numbers: MenSurgE2
First Posted: September 19, 2016    Key Record Dates
Last Update Posted: September 19, 2016
Last Verified: September 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Salvatore Caruso, Policlinico Universitario, Catania:
Estriol
Prolapse
Quality of life
Vaginal health
Vaginal surgery

Additional relevant MeSH terms:
Prolapse
Pathological Conditions, Anatomical